
    
      This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary
      clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain
      containing (PVRIG) as monotherapy and in combination with nivolumab in subjects with advanced
      solid tumors. Cohort expansion will be explored evaluating COM701 monotherapy and in
      combination with nivolumab in subjects with the following select tumor types (Non-Small cell
      lung cancer (NSCLC), Ovarian, Breast (including Triple negative breast cancer (TNBC) and
      endometrial cancer. Other tumor types such as CRC-MSS, CRC-KRAS mutant will be enrolled based
      on emerging clinical activity data.
    
  